Listeria future or investigational therapies: Difference between revisions
(Created page with "{{Listeria}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Infectious disease {{WH}} {{WS}}") |
m (Changes made per Mahshid's request) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
==Modern Relevance/Future Research== | |||
Listeriosis is an opportunistic pathogen: it is most prevalent in the elderly, pregnant mothers, and AIDS patients. With improved healthcare leading to a growing elderly population and extended life expectancies for AIDS patients, physicians are more likely to encounter this otherwise rare infection (only 0.7 per 100,000 healthy people are infected with virulent ''Listeria'' each year). Better understanding the cell biology of Listeria infections, including relevant virulence factors, may help us better treat Listeriosis and other intracytoplasmic parasites. Researchers are now investigating the use of ''Listeria'' as a cancer vaccine, taking advantage of its "ability induce potent innate and adaptive immunity." | |||
===Future treatment options=== | |||
Intralytix has created a virus spray with bacteriophages to be applied to food for the prevention of [[Listeriosis]] by killing six strains of ''[[Listeria monocytogenes|L. monocytogenes]]'' bacterium.<ref>[[Associated Press]] - [http://www.livescience.com/othernews/ap_060821_virus_food.html Viruses Approved for Treating Food]</ref> EBI Food Safety has created and put a similar product on the market, LISTEX™ P100. LISTEX™ P100 prevents Listerios in food by using bacteriophages for killing Listeria. <ref>[[Food Quality News]] - [http://www.foodqualitynews.com/news/ng.asp?n=71423-ebi-bacteriophages-listeria Phage product found effective against Listeria]</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Disease]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:11, 18 September 2017
|
Listeria Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Listeria future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Listeria future or investigational therapies |
|
Risk calculators and risk factors for Listeria future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Modern Relevance/Future Research
Listeriosis is an opportunistic pathogen: it is most prevalent in the elderly, pregnant mothers, and AIDS patients. With improved healthcare leading to a growing elderly population and extended life expectancies for AIDS patients, physicians are more likely to encounter this otherwise rare infection (only 0.7 per 100,000 healthy people are infected with virulent Listeria each year). Better understanding the cell biology of Listeria infections, including relevant virulence factors, may help us better treat Listeriosis and other intracytoplasmic parasites. Researchers are now investigating the use of Listeria as a cancer vaccine, taking advantage of its "ability induce potent innate and adaptive immunity."
Future treatment options
Intralytix has created a virus spray with bacteriophages to be applied to food for the prevention of Listeriosis by killing six strains of L. monocytogenes bacterium.[1] EBI Food Safety has created and put a similar product on the market, LISTEX™ P100. LISTEX™ P100 prevents Listerios in food by using bacteriophages for killing Listeria. [2]